Skip to main content
. 2016 May 2;7(23):35241–35256. doi: 10.18632/oncotarget.9129

Figure 1. Disposition schematic.

Figure 1

The evaluable analysis set included all patients who have a follow-up duration ≥30 days, did not receive adjuvant therapy, have a cell cycle progression (CCP) score, and have follow-up information. FFPE, formalin-fixed, paraffin-embedded; H&E, hematoxylin and eosin.